Physician profile
David Millett
NPI 1437177805
$16,211.25
in general payments reported to CMS, 2019-2025
21 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $212 · 2021: $3,030 · 2022: $954 · 2023: $7,805 · 2024: $2,625 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,018 · Food and Beverage: $4,832 · Travel and Lodging: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,018.00 |
| Food and Beverage | $4,831.55 |
| Travel and Lodging | $1,438.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $5,271.19 | 2022-2025 | Valtoco |
| Neuropace, INC. | $4,842.01 | 2019-2025 | |
| Surgical Theater. INC. | $2,500.00 | 2021 | |
| Sk Life Science, INC. | $1,000.94 | 2021-2025 | Xcopri |
| Ucb, INC. | $629.98 | 2019-2025 | Fintepla, Briviact |
| Abbvie INC. | $465.69 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $185.63 | 2023 | Aptiom |
| Livanova USA, INC. | $185.59 | 2022 | |
| Greenwich Biosciences, INC. | $171.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $155.29 | 2020-2021 | |
| Medtronic USA, INC. | $147.27 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Allergan, INC. | $124.29 | 2020 | |
| Silk Road Medical, INC. | $107.14 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Zimmer Biomet Holdings, INC. | $100.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $78.00 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $45.27 | 2024-2025 | |
| Aquestive Therapeutics, INC. | $23.49 | 2021 | |
| Ricoh USA, INC | $19.21 | 2019 | |
| Zogenix INC. | $16.95 | 2021 | |
| Lilly USA, LLC | $16.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Millett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.